VAS
PTCT icon

Vestmark Advisory Solutions’s PTC Therapeutics PTCT Stock Holding History

Vestmark Advisory Solutions’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
19,902
+4,666
+31% +$337K 0.02% 795
2026
Q1 		$1.04M Sell
15,236
-148
-1% -$10.5K 0.01% 855
2025
Q4 		$1.17M Buy
+15,384
New +$1.12M 0.02% 755

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Vestmark Advisory Solutions's PTCT Position: Q2 2026 in Review

Vestmark Advisory Solutions increased its PTC Therapeutics (PTCT) stake by 31% in Q2 2026, buying an estimated $337K and bringing the position to 19,902 shares worth $1.62M. The position accounts for 0.02% of the portfolio, ranked #795.

Vestmark Advisory Solutions first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Vestmark Advisory Solutions held 19,902 shares of PTC Therapeutics worth $1.62M as of Q2 2026.
  • Vestmark Advisory Solutions bought 4,666 PTC Therapeutics shares in Q2 2026, an estimated $337K.
  • PTC Therapeutics made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #795 holding.
  • Vestmark Advisory Solutions first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.